Delving into the Latest Updates on Human immunoglobulin(Hualan Biological Engineering) with Synapse

The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19. Moreover three substudies have been integrated. Currently, patients will be randomized to receive (hydroxy-)chloroquine (Treatment stopped after reports of safety issues), lopinavir/ritonavir, remdesivir or standard of care. Moreover, these patients are eligible for substudy A (randomized to rivaroxaban 5mg 1-0-1 vs. standard of care), substudy B (renin-angiotensin (RAS) blockade vs. no RAS blockade for patients with blood pressure >120/80mmHg), and substudy C (asunercept vs standard of care, pentglobin vs. standard of care for patients with respiratory deterioration and high inflammatory biomarkers).
Endpoints were chosen based on the master protocol published by the World Health Organisation and include a 7-point scale of clinical performance, mortality, oxygen requirement (both dose and type), duration of hospitalization, viral load and safety.

Start Date16 Apr 2020

Sponsor / Collaborator

Medical University of Vienna

[+3]

100 Clinical Results associated with Human immunoglobulin(Hualan Biological Engineering)

Login to view more data

100 Translational Medicine associated with Human immunoglobulin(Hualan Biological Engineering)

Login to view more data

100 Patents (Medical) associated with Human immunoglobulin(Hualan Biological Engineering)

Login to view more data

4

Literatures (Medical) associated with Human immunoglobulin(Hualan Biological Engineering)

01 Feb 2022·Zhongguo shi yan xue ye xue za zhi

[Clinical Analysis of Acute Myeloid Leukemia Patients with Hemophagocytic Syndrome].

Article

Author: Wang, Ya-Ping ; Zhang, Xue-Ya ; Wu, Shi-Xin

OBJECTIVE:

To investigate the clinical features of acute myeloid leukemia patients with hemophagocytic syndrome.

METHODS:

The clinical data of 2 patients with acute myeloid leukemia complicated with hemophagocytic syndrome were collected, and the clinical characteristics and treatment outcomes were analyzed.

RESULTS:

There were two patients with acute myeloid leukemia, including 1 male and 1 female，aged for 67 and 40 years old，respectively. Hemophagocytic syndrome occurred in one patient after induction therapy for acute myeloid leukemia and one patient after consolidation therapy. Both of the patients with hemophagocytic syndrome showed fever, hemocytopenia, high ferritin, high titer sCD25 levels and hemophagocytes in bone marrow. After achieved anti-infection, glucocorticoid, human immunoglobulin and etoposide regimens treatment, hemophagocytic syndrome was controlled in both of the two patients. One patient failed to induce acute myeloid leukemia and one patient achieved complete remission.

CONCLUSION:

Acute myeloid leukemia complicated with hemophagocytic syndrome is rare. Early identification, early anti-infection combined with HLH94 regimen can control hemophagocytosis and improve prognosis.

01 Mar 2010·Hinyokika kiyo. Acta urologica Japonica

[A case report of toxic shock syndrome after high orchiectomy].

Article

Author: Yoshikawa, Motokiyo ; Matsumoto, Yoshihiro ; Yamada, Atsushi ; Otani, Takeshi ; Yamamoto, Hiroaki ; Maruyama, Yoshio

We report our experience of toxic shock syndrome (TSS) in a 54-year-old male patient after high orchiectomy for testicular cancer. Four days after the surgery, he began to have diarrhea, high fever, and diffuse erythroderma followed by severe hypotension. There were no signs of postsurgical wound infection, so serious drug eruption was suspected. Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the culture of the drain and result of skin biopsy, leading to the diagnosis of TSS. Following treatment with intravenous fluids, antibiotics, human immunoglobulin and corticosteroids, the symptoms went into remission. TSS progresses rapidly and becomes life-threatening if treatment is delayed. Therefore, when TSS is suspected in postsurgical patients who experience fever of 39 degrees C or higher, dermal erythema, shock, treatment should be started promptly.

14 Dec 2006·Journal of autism and developmental disordersQ3 · PSYCHOLOGY

Oral Human Immunoglobulin for Children with Autism and Gastrointestinal Dysfunction: A Prospective, Open-Label Study

Q3 · PSYCHOLOGY

Article

Author: Cindy K. Schneider ; Leon E. Barstow ; F. Javier Enriquez ; Raun D. Melmed ; James Ranger-Moore ; James A. Ostrem

Immunoglobulin secretion onto mucosal surfaces is a major component of the mucosal immune system. We hypothesized that chronic gastrointestinal (GI) disturbances associated with autistic disorder (AD) may be due to an underlying deficiency in mucosal immunity, and that orally administered immunoglobulin would be effective in alleviating chronic GI dysfunction in these individuals. In this pilot study, twelve male subjects diagnosed with AD were evaluated using a GI severity index (GSI) while receiving daily dosing with encapsulated human immunoglobulin. Following eight weeks of treatment, 50% of the subjects met prespecified criteria for response in GI signs and symptoms and showed significant behavioral improvement as assessed by the Autism Behavior Checklist and parent and physician rated Clinical Global Impression of Improvement.

100 Deals associated with Human immunoglobulin(Hualan Biological Engineering)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Autoimmune Diseases	China	Hualan Biological Engineering, Inc.	31 Dec 1997
IgG Deficiency	China	Hualan Biological Engineering, Inc.	31 Dec 1997
Mucocutaneous Lymph Node Syndrome	China	Hualan Biological Engineering, Inc.	31 Dec 1997
Purpura, Thrombocytopenic	China	Hualan Biological Engineering, Inc.	31 Dec 1997

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	Phase 3	China	Hualan Genetic Engineering Co., Ltd.	23 Dec 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data